Form 4: 89bio Director Charles McWherter Acquires Stock Options

Director Charles McWherter of 89bio, Inc. acquires options to purchase 56,400 shares of common stock.

Summary

• On February 3, 2025, Charles McWherter, a director of 89bio, Inc., was granted stock options to purchase 56,400 shares of the company's common stock.
• The exercise price of the options is $9.60 per share.
• The options vest in full on February 1, 2026, contingent upon McWherter's continued service to the company.
• The options expire on February 3, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is a common practice.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is fairly typical, aligning with industry norms for incentivizing long-term commitment.
• The number of shares granted should be compared to similar companies of the same market cap to determine if the grant is excessive or below average.

Stakeholder Impact

• The granting of stock options could have a slightly dilutive effect on existing shareholders.

Key Dates